Why Zenas BioPharma, Inc.’s (ZBIO) Stock Is Down 6.17%
As of Wednesday, September 23, Zenas BioPharma, Inc.’s ZBIO share price has dipped by 6.17%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Commentary & Analysis
Why Zenas BioPharma, Inc.’s (ZBIO) Stock Is Down 7.62%
As of Wednesday, September 23, Zenas BioPharma, Inc.’s ZBIO share price has dipped by 7.62%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Zenas BioPharma, Inc.’s (ZBIO) Stock Is Down 6.84%
As of Thursday, August 13, Zenas BioPharma, Inc.’s ZBIO share price has dipped by 6.84%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Zenas BioPharma, Inc.’s (ZBIO) Stock Is Down 6.82%
As of Thursday, August 13, Zenas BioPharma, Inc.’s ZBIO share price has dipped by 6.82%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Zenas BioPharma, Inc.’s (ZBIO) Stock Is Down 6.62%
As of Thursday, August 13, Zenas BioPharma, Inc.’s ZBIO share price has dipped by 6.62%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | ZBIO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,931.2 | $259.1 | 53% |
|
| Shares Out (Mil) | 63.1 | 54.3 | 53% |
|
| Institutional Ownership | 98.4% | 92.8% | 78% |
|
| Float (Mil) | 45.0 | 42.0 | 45% |
|
| Beta | -1.02 | 0.95 | 1% |
|
| Avg Daily Volume (000s) | 760 | 637 | 63% |
|
| Price Change (52-week) |
56.4% | 52.5% | 86% |
|
| Growth | ZBIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($1.270) | ($5.615) | ($4.660) | |
| Month Ago EPS | ($1.270) | ($5.615) | ($4.660) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | ($1.310) | ($4.333) | ($2.265) | |
| Year/Year Chg | (28.1%) | (33.5%) | (56.2%) | |
| Financials | ZBIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $37 | 2% |
|
| Net Income (TTM) (Mil) | ($484) | ($43) | 3% |
|
| EPS (TTM) | ($9.052) | ($1.600) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($226) | ($32) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $153 | $2 | 81% |
|
| Long-Term Debt (Q1) (Mil) | $297 | $4 | 53% |
|
| Enterprise Value (Q1) (Mil) | $1,776 | $175 | 47% |
|
| Valuation | ZBIO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.60 | 2.54 | 87% |
|
| P/E | na | 18.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ZBIO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.9% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (97.4%) | (47.5%) | 6% |
|
| ROE | (199.0%) | (54.9%) | 4% |
|
| Liabilities to Assets | 64.8% | 29.4% | 60% |
|
| F-Score | 2 | 3 | 7% |
|
Zenas BioPharma, Inc. did not pass any screens on 9/23/2026.
